- Filament Health Corp. (FH) has completed two non-brokered private placements for gross proceeds of $2,500,080
- The offerings included non-brokered private placements of 1,250 convertible debenture units and 9,616,000 units
- Negev Capital was the sole investor in the convertible debenture unit financing
- Filament Health is a clinical-stage natural psychedelic drug development company
- Filament Health (FH) is unchanged on the day, trading at C$0.115 per share
Filament Health Corp. (FH) has completed two non-brokered private placements for gross proceeds of $2,500,080.
The offerings included a non-brokered private placement of 9,616,000 units priced at $0.13 per unit for gross proceeds of $1,250,080 and a non-brokered private placement of 1,250 convertible debenture units priced at $1,000 per debenture for gross proceeds of $1,250,000.
Each unit consisted of one common share and one common share purchase warrant. Each warrant entitles the holder to purchase one additional common share for a period of 36 months.
Each convertible debenture unit includes a $1,000 unsecured convertible debenture and 6,667 warrants. Each warrant entitles the holder to purchase one additional common share for a period of 36 months. Each debenture is convertible into common shares at a price of $0.15.
Negev Capital was the sole investor in the convertible debenture unit financing. Filament Health has agreed to nominate a member of Negev Capital to its Board of Directors.
Filament Health is a clinical-stage natural psychedelic drug development company.
Filament Health (FH) is unchanged on the day, trading at C$0.115 per share.
